• Pierre-Adrien Bolze, Jocelyne Attia, Jérôme Massardier, Michael J Seckl, Leon Massuger, Nienke van Trommel, Isa Niemann, Touria Hajri, Anne-Marie Schott, François Golfier, and EOTTD group.
• University of Lyon 1, University Hospital Lyon Sud, Department of Gynaecological Surgery and Oncology, Obstetrics, Pierre Bénite, France; French Centre for Trophoblastic Diseases, University Hospital Lyon Sud, Pierre Bénite, France. Electronic address: pierre-adrien.bolze@chu-lyon.fr.
• Eur. J. Cancer. 2015 Sep 1; 51 (13): 1725-31.

AbstractGestational trophoblastic disease (GTD) is a spectrum of cellular proliferations arising from trophoblast. Their invasive and metastatic potential sometimes requires chemotherapy and/or surgery. Current management is generally associated with favourable prognosis. Therefore, treatments must be chosen according to the desire for further childbearing of each patient. The European Organisation for Treatment of Trophoblastic Diseases (EOTTD) is dedicated to optimise diagnosis, treatment, follow-up and research in GTD by bringing together knowledge of clinicians and researchers from 29 countries working in the field of GTD in Europe. This study assessed the level of agreement among an expert panel of the EOTTD in order to rationalise the management of patients in Europe. The RAND/UCLA Appropriateness Method was used to combine the best available scientific evidence with the collective judgment of experts to yield a statement regarding the appropriateness of performing a procedure at the level of patient-specific symptoms, medical history and test results. There was an agreement for 54 statements while the experts showed a disagreement for two statements. As there is little evidence from randomised trials on which to base recommendations about management of GTD, many of these recommendations are based on expert opinion derived from changes in management fact that have improved outcomes from nearly 100% fatality to nearly 100% cure rates. However, a large agreement among experts is invaluable to the individual clinician who is struggling to decide whether a fertility-sparing treatment of hydatidiform mole or a low-risk GTN can be chosen and how it must be conducted. Copyright © 2015 Elsevier Ltd. All rights reserved.

22 keywords...

hide…